Vericel Q3 revenue beats estimates on higher MACI product sales
VCEL•Vericel’s third-quarter revenue rose 26% year over year to $85.37 million, beating the $77.95 million estimate. Net income climbed 179% to $14.16 million, and the company raised its 2026 revenue and adjusted EBITDA margin guidance.
1. Revenue and earnings rise
Vericel reported third-quarter revenue of $85.37 million, up 26% year over year and above the $77.95 million analyst estimate. Net income rose 179% to $14.16 million. Adjusted EBITDA was $25.20 million, and gross margin was 73%.
2. MACI drives sales growth
The company said MACI product sales drove revenue growth, marking its sixth consecutive quarter with growth of more than 20%. Burn Care, which includes Epicel and NexoBrid, also posted record quarterly revenue and strong growth.
3. 2026 guidance raised
Vericel raised its 2026 revenue guidance to $344 million-$346 million from $330 million-$340 million. It increased its MACI revenue outlook to $290 million-$292 million from $284 million-$290 million, and its Burn Care outlook to $54 million from $46 million-$50 million. The company also raised its adjusted EBITDA margin guidance.
